During the study period, the applicable Japanese lung cancer treatment guidelines (2016–17) designated chemotherapy as the standard first-line treatment option for patients with advanced NSCLC with PD-L1 TPS <50%, or unknown PD-L1 expression [7,8]. This evidence concerns the gene CD274 and lung cancer.